471 related articles for article (PubMed ID: 27161301)
1. Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?
Prattichizzo F; Giuliani A; De Nigris V; Pujadas G; Ceka A; La Sala L; Genovese S; Testa R; Procopio AD; Olivieri F; Ceriello A
Diabetes Obes Metab; 2016 Sep; 18(9):855-67. PubMed ID: 27161301
[TBL] [Abstract][Full Text] [Related]
2. Endothelial Extracellular Vesicles Produced by Senescent Cells: Pathophysiological Role in the Cardiovascular Disease Associated with all Types of Diabetes Mellitus.
Carracedo J; Alique M; Ramírez-Carracedo R; Bodega G; Ramírez R
Curr Vasc Pharmacol; 2019; 17(5):447-454. PubMed ID: 30124156
[TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications.
Prattichizzo F; Matacchione G; Giuliani A; Sabbatinelli J; Olivieri F; de Candia P; De Nigris V; Ceriello A
Theranostics; 2021; 11(3):1031-1045. PubMed ID: 33391519
[TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular mechanisms of endothelial dysfunction in diabetes.
Roberts AC; Porter KE
Diab Vasc Dis Res; 2013 Nov; 10(6):472-82. PubMed ID: 24002671
[TBL] [Abstract][Full Text] [Related]
5. CD31
Prattichizzo F; De Nigris V; Sabbatinelli J; Giuliani A; Castaño C; Párrizas M; Crespo I; Grimaldi A; Baranzini N; Spiga R; Mancuso E; Rippo MR; Procopio AD; Novials A; Bonfigli AR; Garavelli S; La Sala L; Matarese G; de Candia P; Olivieri F; Ceriello A
Diabetes; 2021 Jan; 70(1):240-254. PubMed ID: 33097483
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Vesicles and Insulin Resistance: A Potential Interaction in Vascular Dysfunction.
Sáez T; Toledo F; Sobrevia L
Curr Vasc Pharmacol; 2019; 17(5):491-497. PubMed ID: 30277159
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
Eriksson L; Nyström T
Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
[TBL] [Abstract][Full Text] [Related]
8. Vascular complications in diabetes: Microparticles and microparticle associated microRNAs as active players.
Alexandru N; Badila E; Weiss E; Cochior D; Stępień E; Georgescu A
Biochem Biophys Res Commun; 2016 Mar; 472(1):1-10. PubMed ID: 26891868
[TBL] [Abstract][Full Text] [Related]
9. Targeting the endothelium to prevent diabetes-related atherosclerosis.
Kearney MT
Diab Vasc Dis Res; 2010 Jul; 7(3):177. PubMed ID: 20699387
[No Abstract] [Full Text] [Related]
10. Secretion of microvesicular miRNAs in cellular and organismal aging.
Weilner S; Schraml E; Redl H; Grillari-Voglauer R; Grillari J
Exp Gerontol; 2013 Jul; 48(7):626-33. PubMed ID: 23283304
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potentials of Extracellular Vesicles for the Treatment of Diabetes and Diabetic Complications.
Hu W; Song X; Yu H; Sun J; Zhao Y
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708290
[TBL] [Abstract][Full Text] [Related]
12. Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?
Coco C; Sgarra L; Potenza MA; Nacci C; Pasculli B; Barbano R; Parrella P; Montagnani M
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212911
[TBL] [Abstract][Full Text] [Related]
13. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients.
Steffensen LB; Feddersen S; Preil SR; Rasmussen LM
Cardiovasc Diabetol; 2018 May; 17(1):72. PubMed ID: 29773082
[TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction and its role in diabetic vascular disease.
Hartge MM; Kintscher U; Unger T
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):551-60, viii-ix. PubMed ID: 16959585
[TBL] [Abstract][Full Text] [Related]
15. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.
Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P
Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217
[TBL] [Abstract][Full Text] [Related]
16. Macro- and microvascular endothelial dysfunction in diabetes.
Shi Y; Vanhoutte PM
J Diabetes; 2017 May; 9(5):434-449. PubMed ID: 28044409
[TBL] [Abstract][Full Text] [Related]
17. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Teerlink T; Gram J; Winther K; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 May; 158(5):631-41. PubMed ID: 18426821
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Otsuki M; Goya K; Kasayama S
Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
[TBL] [Abstract][Full Text] [Related]
19. "Inflammaging" as a Druggable Target: A Senescence-Associated Secretory Phenotype-Centered View of Type 2 Diabetes.
Prattichizzo F; De Nigris V; La Sala L; Procopio AD; Olivieri F; Ceriello A
Oxid Med Cell Longev; 2016; 2016():1810327. PubMed ID: 27340505
[TBL] [Abstract][Full Text] [Related]
20. The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
Porter KE; Riches K
Clin Sci (Lond); 2013 Aug; 125(4):167-82. PubMed ID: 23634936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
